ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,797 | +38.3% | 9,840 | +79.0% | 0.00% | – |
| Q2 2023 | $253,578 | +8.8% | 5,497 | +40.8% | 0.00% | – |
| Q2 2022 | $233,000 | -17.1% | 3,905 | +1.0% | 0.00% | – |
| Q1 2022 | $281,000 | +2.6% | 3,868 | +18.7% | 0.00% | – |
| Q4 2021 | $274,000 | -9.6% | 3,258 | -3.0% | 0.00% | – |
| Q3 2021 | $303,000 | +4.8% | 3,358 | +10.9% | 0.00% | – |
| Q2 2021 | $289,000 | -29.9% | 3,027 | -16.3% | 0.00% | -100.0% |
| Q1 2021 | $412,000 | -20.5% | 3,616 | -3.3% | 0.00% | 0.0% |
| Q4 2020 | $518,000 | +107.2% | 3,741 | +23.0% | 0.00% | 0.0% |
| Q3 2020 | $250,000 | -1.2% | 3,041 | -6.0% | 0.00% | 0.0% |
| Q2 2020 | $253,000 | +18.8% | 3,235 | -32.4% | 0.00% | 0.0% |
| Q1 2020 | $213,000 | -72.9% | 4,785 | -57.8% | 0.00% | -50.0% |
| Q1 2019 | $786,000 | -80.1% | 11,327 | -70.6% | 0.00% | -80.0% |
| Q2 2015 | $3,940,000 | – | 38,482 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |